Clinical Studies

Real-time continuous glucose monitoring (CGM) significantly reduces severe hypoglycemia in hypoglycemia-unaware patients with type 1 diabetes.

You are here

In hypoglycemia unaware patients, CGM provides the required information needed for enhanced decision making support to improve glycemic control and help eliminate severe hypoglycemia. In this observational study, severe hypoglycemia incidents were reduced by 93% in adults with hypoglycemia unawareness using RT-CGM.

ABSTRACT

Objective To evaluate the effect of continuous glucose monitoring (CGM) on the frequency of severe hypoglycemia (SH) in patients with established hypoglycemia unawareness.

Research and Design Methods We conducted a retrospective audit of 35 patients with type 1 diabetes and problematic hypoglycemia unawareness, despite optimized medical therapy (continuous subcutaneous insulin infusion/multiple daily insulin injections), who used CGM for >1 year.

Results Over a 1-year follow-up period, the median rates of SH were reduced from 4.0 (interquartile range [IQR] 0.75-7.25) episodes/patient-year to 0.0 (0.0-1.25) episodes/patient-year (P < 0.001), and the mean (±SD) rates were reduced from 8.1 ± 13 to 0.6 ± 1.2 episodes/year (P = 0.005). HbA1c was reduced from 8.1 ± 1.2% to 7.6 ± 1.0% over the year (P = 0.005). The mean Gold score, measured in 19 patients, did not change: 5.1 ± 1.5 vs. 5.2 ± 1.9 (P = 0.67).

Conclusions In a specialist experienced insulin pump center, in carefully selected patients, CGM reduced SH while improving HbA1c but failed to restore hypoglycemia awareness.

Source: Choudhary P, Ramasamy S, Green L et al. Real-Time Continuous Glucose Monitoring Significantly Reduces Severe Hypoglycemia in Hypoglycemia-Unaware Patients With Type 1 Diabetes. Diabetes Care. 2013;36(12):4160-4162.

View the article.

More Clinical Studies

This paper reviews the features and available evidence supporting use of both real-time continuous glucose monitoring (rtCGM) and intermittent scanning CGM (isCGM), offering guidance for patient selection for each type of system. RtCGM systems (...

HypoDE study shows that Dexcom CGM use significantly reduces hypoglycemia in MDI patients.1 Background

Continuous glucose monitoring (CGM) clinical trials to date have largely excluded individuals with severe hypoglycemia (SH) or...

In this open-label, single-arm, multicenter clinical study, the Dexcom G4® PLATINUM Continuous Glucose Monitoring (CGM) System (which uses the same software 505 as the Dexcom G5 Mobile CGM System) was evaluated for accuracy in 51...